E-Home Household Service Holdings Limited — Form 6-K Summary
Filing date: November 18, 2022. Reporting period: Month of November 2022; accompanying financial information is as of June 30, 2022, with comparative information as of June 30, 2021.
Business Context and Purpose
E-Home filed the Form 6-K to furnish financial statements related to Zhongrun (Fujian) Pharmaceutical Co., Ltd. and unaudited pro forma combined financial information for E-Home. The exhibits are intended for incorporation by reference into E-Home’s Form F-3 registration statement and other specified Securities Act registration statements.
Financial Information and Key Metrics
- Exhibit 99.1 contains audited financial statements of Zhongrun (Fujian) Pharmaceutical Co., Ltd. as of June 30, 2022 and 2021.
- Exhibit 99.2 contains unaudited pro forma combined financial information of E-Home as of June 30, 2022.
- The filing text provided does not include clear values for revenue, profit, cash flow, margins, debt, liquidity, assets, liabilities, or other financial metrics.
Material Changes, Outlook, and Risks
The filing text does not describe operating performance, material changes versus the prior comparable period, management guidance, outlook, contingencies, or specific risks. It primarily furnishes financial exhibits and an auditor consent for registration-statement purposes.
Exhibits
| Exhibit | Description |
|---|---|
| 99.1 | Audited financial statements of Zhongrun (Fujian) Pharmaceutical Co., Ltd. as of June 30, 2022 and 2021 |
| 99.2 | Unaudited pro forma combined financial information of E-Home as of June 30, 2022 |
| 99.3 | Consent of TPS Thayer, LLC, independent auditors |
Important Facts for Investor Verification
- Review Exhibit 99.1 for Zhongrun’s audited results, financial position, cash flows, and audit disclosures.
- Review Exhibit 99.2 for the assumptions, transaction adjustments, and resulting pro forma combined figures.
- Confirm how the furnished exhibits relate to E-Home’s Form F-3 and any other registration statements.
- Assess any acquisition, consolidation, related-party, or pharmaceutical-business implications disclosed in the exhibits, which are not included in the provided filing text.